{"id":4762,"date":"2025-10-10T15:17:22","date_gmt":"2025-10-10T12:17:22","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4762"},"modified":"2025-11-03T20:18:13","modified_gmt":"2025-11-03T17:18:13","slug":"wve-n531-exon-skipping-therapy-phase-2-clinical-trial-nct07209332","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/wve-n531-exon-skipping-therapy-phase-2-clinical-trial-nct07209332\/","title":{"rendered":"Comienza el ensayo cl\u00ednico de fase 2 de la terapia de omisi\u00f3n de ex\u00f3n WVE-N531 para la distrofia muscular de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Wave Life Sciences Ltd. anunci\u00f3 en su sitio web ClinicalTrials.gov que un ensayo cl\u00ednico de fase 2 de WVE-N531 (terapia de omisi\u00f3n de ex\u00f3n 53) comenzar\u00e1 en noviembre de 2025 con 175 participantes en Jordania y el Reino Unido.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Tabla de contenido<\/h2><nav><ul><li><a href=\"#what-is-wve-n-531-exon-skipping-therapy\">\u00bfQu\u00e9 es la terapia de omisi\u00f3n de exones WVE-N531?<\/a><\/li><li><a href=\"#wve-n-531-exon-skipping-therapy-phase-2-nct-07209332\">Terapia de omisi\u00f3n de ex\u00f3n WVE-N531, fase 2 \u2013 NCT07209332<\/a><\/li><li><a href=\"#how-to-participate-in-the-wve-n-531-clinical-trial\">C\u00f3mo participar en el ensayo cl\u00ednico WVE-N531<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-wve-n-531-exon-skipping-therapy\">\u00bfQu\u00e9 es la terapia de omisi\u00f3n de exones WVE-N531?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>WVE-N531 es una terapia de omisi\u00f3n de ex\u00f3n en investigaci\u00f3n que se est\u00e1 desarrollando como una posible terapia para pacientes con DMD susceptibles de omisi\u00f3n del ex\u00f3n 53.<\/strong> El WVE-N531 se dise\u00f1\u00f3 utilizando las mejores modificaciones qu\u00edmicas de oligonucle\u00f3tidos de Wave, incluyendo la qu\u00edmica de la cadena principal de PN. El WVE-N531 ha recibido la Designaci\u00f3n de Medicamento Hu\u00e9rfano y la Designaci\u00f3n de Enfermedad Pedi\u00e1trica Rara de la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leer m\u00e1s<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/es\/mutations-and-deletions-amenable-to-exon-53-skipping-therapies-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Mutaciones y deleciones susceptibles de terapias de omisi\u00f3n del ex\u00f3n 53 para la distrofia muscular de Duchenne<\/a><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"847\" height=\"1024\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-847x1024.jpg\" alt=\"Mutaciones y deleciones susceptibles de terapias de omisi\u00f3n del ex\u00f3n 53 para la distrofia muscular de Duchenne\" class=\"wp-image-4566\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-847x1024.jpg 847w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-248x300.jpg 248w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-768x929.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1270x1536.jpg 1270w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1693x2048.jpg 1693w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-10x12.jpg 10w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-347x420.jpg 347w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-150x181.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-300x363.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-696x842.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1068x1292.jpg 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping-1920x2323.jpg 1920w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/09\/amenable-to-exon-53-skipping.jpg 1984w\" sizes=\"auto, (max-width: 847px) 100vw, 847px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"wve-n-531-exon-skipping-therapy-phase-2-nct-07209332\">Terapia de omisi\u00f3n de ex\u00f3n WVE-N531, fase 2 \u2013 NCT07209332<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Este es un estudio de extensi\u00f3n abierta (OLE) de fase 2 para evaluar la seguridad, la tolerabilidad, la eficacia, la farmacocin\u00e9tica y la farmacodinamia (PD) a largo plazo a trav\u00e9s de posibles biomarcadores exploratorios de WVE-N531 intravenoso (IV) en pacientes con DMD que participaron en otro estudio de WVE-N531.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Inicio del estudio (estimado)<\/strong>: 2025-11<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n primaria (estimada)<\/strong>: 2029-03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Finalizaci\u00f3n del estudio (estimada)<\/strong>: 2029-03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 175<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tipo de estudio<\/strong>:Intervencionista<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ubicaci\u00f3n<\/strong>Jordania, Reino Unido<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Edades elegibles para estudiar<\/strong>: Ni\u00f1o, Adulto, Adulto mayor<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Criterios principales de inclusi\u00f3n y exclusi\u00f3n. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07209332\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07209332<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-to-participate-in-the-wve-n-531-clinical-trial\">C\u00f3mo participar en el ensayo cl\u00ednico WVE-N531<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Para participar en el ensayo cl\u00ednico de fase 2 de la terapia de omisi\u00f3n de exones WVE-N531, puede utilizar la informaci\u00f3n de contacto que aparece a continuaci\u00f3n. <strong>M\u00e1s informaci\u00f3n<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/es\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u00bfC\u00f3mo participar en ensayos cl\u00ednicos para Duchenne (DMD)?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre<\/strong>:Operaciones cl\u00ednicas<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de tel\u00e9fono<\/strong>: 855-215-4687<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Correo electr\u00f3nico<\/strong>: ensayos cl\u00ednicos@wavelifesci.com<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leer m\u00e1s<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/es\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ensayos cl\u00ednicos para la distrofia muscular de Duchenne (Lista de todas las investigaciones)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Wave Life Sciences Ltd. announced on its ClinicalTrials.gov website that a phase 2 clinical trial of WVE-N531 (Exon 53 Skipping Therapy) will begin in November 2025 with 175 participants in Jordan and the United Kingdom. What is WVE-N531 Exon Skipping Therapy WVE-N531 is an investigational exon skipping therapy being developed as a potential therapy for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4769,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,155,154,328,422,153,327],"class_list":["post-4762","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-exon-53","tag-exon-53-skipping","tag-exon-53-skipping-therapy","tag-exon-53-treatment","tag-wave-life-sciences","tag-wve-n531"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4762"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4762\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4769"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4762"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}